Typical — Vs Atypical Hemolytic Uremic Syndrome

Hemolytic uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. While this definition is clear, the syndrome is not a single disease but rather a spectrum of conditions with vastly different etiologies, treatments, and prognoses. The critical distinction lies between typical HUS, also known as Shiga toxin-producing E. coli HUS (STEC-HUS), and atypical HUS (aHUS). Although they share a common final pathway of endothelial damage and microvascular thrombosis, their underlying mechanisms, clinical triggers, and long-term outcomes diverge so significantly that they are best understood as two distinct disorders: one an acute, often self-limited infection, the other a chronic, life-threatening genetic disease of complement dysregulation.

Unlike Typical HUS, aHUS is insidious:

E. coli ) Genetic (complement dysregulation) Prodrome Bloody diarrhea (usually) None (usually), or upper respiratory infection Frequency ~90-95% of cases ~5-10% of cases (Rare) Recurrence Rare (usually one-time) Common (chronic/relapsing) Prognosis Good recovery with supportive care High risk of ESRD, dialysis, death Main Treatment Supportive (fluids, dialysis) Eculizumab (complement inhibitor) Detailed Breakdown Typical HUS (STEC-HUS) Epidemiology: Primarily affects children under 10, often after consuming contaminated food. Mechanism: Shiga toxins enter the bloodstream, bind to endothelial cells, and cause thrombosis (clotting) in small vessels. Outcome: Most children recover well with supportive treatment. ashpublications.org +2 Atypical HUS (aHUS) Epidemiology: Can affect all ages, often familial or sporadic. Mechanism: Uncontrolled alternative complement pathway activation leads to system-wide endothelial damage, particularly in the kidneys, but can affect the brain and heart. Management: Requires rapid initiation of complement inhibition therapy (e.g., eculizumab) to prevent irreversible organ damage. Complications: High rates of chronic kidney disease (CKD) and end-stage renal disease (ESRD). National Institutes of Health (.gov) +4 When to Suspect aHUS Atypical HUS should be suspected if a patient has TMA symptoms (anemia, low platelets, kidney damage) but tests negative for Shiga toxin and possesses normal ADAMTS13 activity (to rule out TTP). ScienceDirect.com +1 Note: Some experts argue for abandoning "atypical HUS" in favor of more specific terms like "complement-mediated TMA," as it better reflects the underlying mechanism. ScienceDirect.com This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. typical vs atypical hemolytic uremic syndrome